Drug Profile
Research programme: acne therapies - Corixa
Latest Information Update: 15 Aug 2007
Price :
$50
*
At a glance
- Originator Corixa Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acne
Most Recent Events
- 18 Apr 2001 New profile
- 18 Apr 2001 Preclinical development for Acne in USA (unspecified route)